Sugi Predict

Sugi Predict / Compounds / SCHEMBL791727

SCHEMBL791727

SCHEMBL791727

COCCN1CCC(C(=O)O)CC1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 3/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ HSD11B1 P28845 1/20 0.45
▸ HRH3 Q9Y5N1 1/20 0.44
▸ S1PR5 Q9H228 1/20 0.42
▸ SLC18A3 Q16572 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ KDM1A O60341 1/20 0.40
▸ WNT1 P04628 1/20 0.40
▸ GSK3B P49841 1/20 0.40
▸ DYRK1A Q13627 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ PARP1 P09874 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4675628 0.98 LTA4H (0.49) LTA4HSMN1; SMN2HSD11B1HRH3S1PR5
SCHEMBL4960236 0.89 SLC6A11 (0.48) LTA4HS1PR5MEN1KMT2A
SCHEMBL4957931 0.89 SLC6A11 (0.48) LTA4HS1PR5MEN1KMT2A
SCHEMBL4957925 0.89 SLC6A11 (0.48) LTA4HS1PR5MEN1KMT2A
SCHEMBL14809721 0.89 HRH3 (0.51) LTA4HSMN1; SMN2HRH3S1PR5KMT2A
Hydrochloric Acid SCHEMBL14810904 0.88 HRH3 (0.50) LTA4HSMN1; SMN2HRH3S1PR5KMT2A
SCHEMBL12437054 0.87 SMN1; SMN2 (0.47) LTA4HSMN1; SMN2HSD11B1SLC18A3TDP1
SCHEMBL1438744 0.84 SMN1; SMN2 (0.66) LTA4HSMN1; SMN2HSD11B1HRH3GAA
SCHEMBL9912397 0.84 TP53 (0.50) LTA4HSMN1; SMN2HSD11B1WNT1GSK3B
Hydrochloric Acid SCHEMBL28743044 0.82 SMN1; SMN2 (0.64) LTA4HSMN1; SMN2HSD11B1HRH3GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423383-B1 PYRIDINE SUBSTITUTED FURAN DERIVATIVES AS RAF KINASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2008-08-06 — — EP claimed
US-7375105-B2 Pyridine substituted furan derivatives as Raf kinase inhibitors SMITHKLINE BEECHAM P.L.C. (GB) 2008-05-20 — — US claimed
EP-1761542-B1 OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS HOFFMANN LA ROCHE (CH) 2008-01-02 — — EP claimed
US-20070135433-A1 IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS DEAN DAVID K 2007-06-14 — — US claimed
EP-1761542-A2 OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2007-03-14 — — EP claimed
WO-2005121145-A2 OCTAHYDRO-PYRROLO[3,4-C] DERIVATIVES AND THEIR USE AS ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-22 — — WO claimed
US-20040248896-A1 Pyridine substituted furan derivatives as raf kinase inhibitors SMITHKLINE BEECHAM P.L.C. (GB) 2004-12-09 — — US claimed
US-20250042914-A1 PIKFYVE KINASE INHIBITOR HANMI PHARM. CO., LTD. (KR) 2025-02-06 — — US disclosed
EP-4410795-A1 PIKFYVE KINASE INHIBITOR Hanmi Pharm. Co., Ltd. (KR) 2024-08-07 — — EP disclosed
CN-118019744-A PIKfyve kinase inhibitors 韩美药品株式会社 2024-05-10 — — CN disclosed
WO-2023055181-A1 PIKFYVE KINASE INHIBITOR 한미약품 주식회사 2023-04-06 — — WO disclosed
US-9475822-B2 Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-10-25 — — US disclosed
US-9475822-B2 Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-10-25 — — US disclosed
EP-1423383-A1 PYRIDINE SUBSTITUTED FURAN DERIVATIVES AS RAF KINASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2004-06-02 — — EP disclosed
US-20040038964-A1 Imidazole derivatives as raf kinase inhibitors SMITHKLINE BEECHAM P.L.C. (GB) 2004-02-26 — — US disclosed
CN-1471523-A Imidazole derivatives as Raf kinase inhibitors ʷ 2004-01-28 — — CN disclosed
WO-2003086467-A1 CANCER TREATMENT METHOD COMPRISING ADMINISTERING AN ERB-FAMILY INHIBITOR AND A RAF AND/OR RAS INHIBITOR SMITHKLINE BEECHAM CORPORATION (US) 2003-10-23 — — WO disclosed
EP-1318992-A1 IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2003-06-18 — — EP disclosed
WO-2003022838-A1 PYRIDINE SUBSTITUTED FURAN DERIVATIVES AS RAF KINASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2003-03-20 — — WO disclosed
WO-2002024680-A1 IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS SMITHKLINE BEECHAM P.L.C. (GB) 2002-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248896-A1 Pyridine substituted furan derivatives as raf kinase inhibitors BRAF, RAF1, ARAF LTA4H 3348/4885SMN1; SMN2 976/4885HSD11B1 1002/4885
US-20250042914-A1 PIKFYVE KINASE INHIBITOR PIKFYVE, PIP4K2B, PIP4K2C LTA4H 4242/4885SMN1; SMN2 3220/4885HSD11B1 3045/4885
US-20070135433-A1 IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF LTA4H 2665/4885SMN1; SMN2 2433/4885HSD11B1 3270/4885
US-20040038964-A1 Imidazole derivatives as raf kinase inhibitors BRAF, RAF1, ARAF LTA4H 2414/4885SMN1; SMN2 2075/4885HSD11B1 2788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.